Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Understanding the 2020 Corona Virus Economic Crisis
By William Poole
Dear Dr. David E. Marcinko,
Thank you for your interest in the Merk Perspective.
Merk Senior Economic Adviser and former St. Louis Fed President William Poole shares his thoughts on how to assess the economic impact of the Corona virus, pointing out in what ways it is different from past crises.
There are several aspects of the crisis that deserve separate attention. Many will seem obvious but nonetheless need to be made explicit to yield a thorough analysis.
***
***
***
Axel Merk
President and Chief Investment Officer
Merk Investments
***
Share this:
Filed under: Health Economics, Health Insurance, Quality Initiatives | Tagged: Corona Virus Economic Crisis, Covid-19, Merk, William Poole |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
U.S. Economy:
Many economists are no longer debating whether we’ll have a recession because of the coronavirus … the questions now are 1) how bad will the recession be and 2) how quickly can we recover.
Dr. David E. Marcinko MBA
LikeLike
$1,335.9 Million is the Mean R&D Investment Needed to Bring a Drug to Market
JAMA recently released a study on the research and development investment need to bring a new drug to market. Here are some key findings from the report:
• The median research and development investment to bring a drug to market was $985.3 million.
• The mean investment to bring a new drug to market was was estimated at $1335.9 million.
• For nervous system agents, the median investment estimate was $765.9 million.
• The median investment was $2771.6 million for antineoplastic and immunomodulating agents.
Source: JAMA, March 3, 2020
LikeLike